JP3431300007
© Globe Newswire
13.01.2026
45650
LISTED
XJPX
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa
News Preview
Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX142, in development for the treatment...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
45650
LISTED
XJPX
Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
News Preview
Tokyo, Japan and Cambridge, UK, 8 January 2026 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that it has entered an exclusive licensing agreement for the development, manufacturing and commercialization of vamorolone for the treatment of Duchenne Muscular Dystrophy (DMD) in Japan, South Korea, Australia and New Zealand...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.12.2025
45650
LISTED
XJPX
Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia
News Preview
Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer Ingelheim has informed the Company of its decision not to exercise its exclusive option to license Nxera’s GPR52 agonist program for schizophrenia, including the Phase 2 ready lead compound NXE0048149 (“NXE’149...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
19.11.2025
45650
LISTED
XJPX
Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan
News Preview
Tokyo, Japan and Cambridge, UK, 19 November 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) announces that its Board of Directors have decided to replace the current Restricted Share Unit (“RSU”) Plan with the Employee Stock Ownership Plan (J-ESOP) (hereinafter referred to as the "Plan" and a trust established under the trust agreem...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
17.11.2025
45650
LISTED
XJPX
Nxera Pharma Shares Video Interviews with Major Shareholders on Its Official YouTube Channel
News Preview
Tokyo, Japan and Cambridge and London, UK, 17 November 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces the release of two video interviews with its major shareholders, available on the Company’s official YouTube channel....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.11.2025
45650
LISTED
XJPX
Nxera Announces Focused Restructuring to Enhance Path to Profitability
News Preview
Tokyo, Japan and Cambridge and London, UK, 17 November 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announced a focused restructuring designed to concentrate investment and resources on efficient platforms, programs and products with the greatest value creation potential. Alongside a focus on prioritized programs, Nxera...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
45650
LISTED
XJPX
Nxera Pharma to Host R&D Day 2025
News Preview
Tokyo, Japan and Cambridge, UK, 4 November 2025 – Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today announces that it will hold an R&D Day on 18 November 2025 at 17:00 JST....
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
45650
LISTED
XJPX
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2025
News Preview
Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference on Monday, 17 November at 12:00 p.m. GMT / 7:00 a.m. ET / 9:00 p.m. JST. During the event, Mr. Cargill wil...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
45650
LISTED
XJPX
Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ® 25 and 50 mg
News Preview
Tokyo, Japan and Cambridge and London, UK, 31 October 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that Nxera Pharma Japan Co., Ltd. (a wholly owned subsidiary of the Company) has received a manufacturing approval partial amendment with respect to QUVIVIQ® (daridorexant) 25 and 50 mg (“the Product”). Daridorexant was...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
45650
LISTED
XJPX
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025
News Preview
Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2025. The full report can be found here....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2025
45650
LISTED
XJPX
Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO
News Preview
Tokyo, Japan and Cambridge, UK, 21 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) announces that its partner, Cancer Research UK, presented data from the successfully completed Phase 1 part of the ongoing Phase 1/2a clinical trial (NCT05944237) of Nxera’s immunotherapy drug HTL0039732 (also known as NXE0039732) at the European So...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.09.2025
45650
LISTED
XJPX
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
News Preview
Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
16.09.2025
45650
LISTED
XJPX
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
News Preview
Tokyo, Japan and Cambridge and London, UK, 17 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) and Cancer Research UK announce that the first patient has been dosed in a Phase 2a clinical trial (NCT05944237) evaluating Nxera’s investigational immunotherapy drug HTL0039732 (also known as NXE0039732) for advanced solid tum...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2025
45650
LISTED
XJPX
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
News Preview
Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2025. The full report can be found here....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.07.2025
45650
LISTED
XJPX
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
News Preview
Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
45650
LISTED
XJPX
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
News Preview
Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-’568) as a potential treatment for schizophrenia, resulting in a payment of US$15 mill...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.06.2025
45650
LISTED
XJPX
Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
News Preview
Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company (“Lilly”) targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2025
45650
LISTED
XJPX
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
News Preview
Tokyo, Japan and Cambridge, UK, 29 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Sc...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.04.2025
45650
LISTED
XJPX
Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia
News Preview
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568 (NBI-’568), an investigational oral muscarinic M4 selecti...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.04.2025
45650
LISTED
XJPX
Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations
News Preview
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces the appointment of Shinya Tsuzuki, as Head of Investor Relations. Mr. Tsuzuki will lead Nxera’s Investor Relations (IR) team in Japan and report to the Company’s Chief Financial Officer, Hironoshin Nomura....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.04.2025
45650
LISTED
XJPX
Nxera Pharma Announces Appointments to its Executive Leadership Team
News Preview
Tokyo, Japan and Cambridge, UK, 1 April 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces two new appointments to its Leadership team: Mr. Kiyoshi Kaneko, is appointed as Chief Commercial Officer (CCO), and Ms. Mariko Nakafuji is promoted into the role of Chief Legal Officer (CLO)....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.03.2025
45650
LISTED
XJPX
Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder
News Preview
Tokyo, Japan and Cambridge, UK, 25 March 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a potent, selective and orally available mGluR5 negative allosteric modulator (NAM), for the treatment of alcohol use disorder (Clinical Trial ID: NCT06648...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.02.2025
45650
LISTED
XJPX
Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan
News Preview
Tokyo, Japan and Cambridge, UK, 28 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has entered a license, supply and commercialization agreement with Holling Bio-Pharma Corp. (“Holling”) for daridorexant in Taiwan....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.02.2025
45650
LISTED
XJPX
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris
News Preview
Tokyo, Japan and Cambridge, UK, 28 February 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) has entered an assignment agreement with Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Pharmaceuticals Ltd (“Idorsia”), regarding the development and commercialization of cenerimod, a clinical-stage immunology candidate for aut...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.01.2025
45650
LISTED
XJPX
Nxera Pharma Webinar Presentation for FY2024 Financial Results
News Preview
Tokyo, Japan and Cambridge, UK, 23 January 2025 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the year ended 31 December 2024 on Friday, 14 February 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2025
45650
LISTED
XJPX
Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio
News Preview
Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”) regarding the clinical development of its partnered muscarinic agonist portfolio. These updates were presented by Neurocrine at the 43rd Annual J.P....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.12.2024
45650
LISTED
XJPX
Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Tokyo, Japan and Cambridge, UK, 20 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Chris Cargill, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, 15 January 2025 at 3:00 p.m. PST....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
45650
LISTED
XJPX
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia
News Preview
Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Shionogi & Co., Ltd. (“Shionogi”) today announce that QUVIVIQ™ (daridorexant) 25 and 50 mg has been launched and is now available in Japan as a new treatment for adults with insom...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2024
45650
LISTED
XJPX
Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea
News Preview
Tokyo, Japan and Cambridge, UK, 5 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces randomization of the first patient in a Phase 3 clinical trial evaluating daridorexant, its novel dual orexin receptor antagonist, for the treatment of adult patients in So...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
45650
LISTED
XJPX
Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist
News Preview
Tokyo, Japan and Cambridge, UK, 13 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes that Centessa Pharmaceuticals has initiated a Phase 2 trial of ORX750, an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist for the...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
45650
LISTED
XJPX
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
News Preview
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (G...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2024
45650
LISTED
XJPX
Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024
News Preview
Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024 held yesterday in Tokyo....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2024
45650
LISTED
XJPX
Nxera Pharma to Host R&D Day 2024
News Preview
Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2024
45650
LISTED
XJPX
Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
News Preview
Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Dr. Makoto Sugita, M.D., Ph.D., MBA, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) o...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2024
45650
LISTED
XJPX
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan
News Preview
Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Nxera Pharma Japan Co., Ltd. (“NPJ”) has entered a new commercial partnership agreement with Shionogi & Co., Ltd. (“Shionogi”), regarding the distribution and sales for Q...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2024
45650
LISTED
XJPX
Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
News Preview
Tokyo, Japan and Cambridge, UK, 24 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Nxera Pharma Japan Co., Ltd. (“NPJ”) has received approval from the Ministry of Health, Labour and Welfare of Japan (“MHLW”) of its New Drug Application (“NDA”) for QUVIVI...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.09.2024
45650
LISTED
XJPX
Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO
News Preview
Tokyo, Japan and Cambridge and London, UK, 13 September 2024 – Nxera Pharma (TSE: 4565, “Nxera”) and Cancer Research UK announce an upcoming presentation on the ongoing Phase 1/2a clinical trial (NCT05944237) of Nxera’s immunotherapy drug HTL0039732 (also known as NXE0039732) at the European Society for Medical Oncology Congress (ESMO) 2024, taking...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.09.2024
45650
LISTED
XJPX
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
News Preview
Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$35 million payment from Neurocrine Biosciences (‘Neurocrine’), triggered by the successful completion of the Phase 2 trial with NBI-1117568 (NBI-‘568)...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2024
45650
LISTED
XJPX
Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
News Preview
Tokyo, Japan and Cambridge, UK, 28 August 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes the announcement by its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX) that NBI-1117568 (NBI-‘568) has delivered positive topline results from its Phase 2 clinical s...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.08.2024
45650
LISTED
XJPX
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024
News Preview
Tokyo, Japan and Cambridge, UK, 9 August 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2024. The full report can be found here....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2024
45650
LISTED
XJPX
Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
News Preview
Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2024 on Friday, 9 August 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
45650
LISTED
XJPX
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
News Preview
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million to Nxera....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2024
45650
LISTED
XJPX
Nxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023
News Preview
Tokyo, Japan and Cambridge, UK, 18 June 2024 – Nxera Pharma (“Nxera” or “the Company”; TSE 4565), today announces the publication of its Annual Report and its Environment, Social & Governance (ESG) Report for the year ended 31 December 2023....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2024
45650
LISTED
XJPX
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
News Preview
Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals pursuant to a license agreement regarding Nxera technology used to help design Centessa’s novel orexin receptor 2 (OX2R) agonist, ORX750. The mil...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2024
45650
LISTED
XJPX
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
News Preview
Tokyo, Japan, Oxford and Cambridge, UK, 30 May 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) and PrecisionLife, the Causal AI precision medicine company, today announce the expansion of their strategic R&D partnership into auto-immune disorders with the potential to identify new drug targets for the treatment of complex, chronic conditions....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2024
45650
LISTED
XJPX
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
News Preview
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, announced that it has initiated its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pha...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2024
45650
LISTED
XJPX
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
News Preview
...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
